Recently Featured

Danish agency NoA Health appoints Louisa Lee as CEO to spearhead global expansion

March 15, 2026
NoA Health has appointed Louisa Lee as its new CEO, a strategic move aimed at accelerating the agency’s global expansion efforts. Lee, who brings extensive experience from her previous roles at Novo Nordisk and Pfizer, is expected to leverage her industry insights to enhance NoA Health’s market presence. This leadership change comes at a critical…

FDA Warns of Hidden Drug Ingredients in Artri Ajo Rey and Artri Ajo King

March 15, 2026
The Food and Drug Administration (FDA) has issued a warning regarding the potential dangers associated with Artri Ajo Rey and Artri Ajo King, products marketed for joint pain and arthritis relief. These items, which are available on various online platforms such as Amazon and possibly in retail outlets, may contain undisclosed pharmaceutical ingredients that could…

Sanofi Strikes $1.5B Global Licensing Deal for Sino Biopharm’s First-in-Class JAK/ROCK Asset

March 14, 2026
Sanofi has entered into a significant $1.53 billion licensing agreement with Sino Biopharmaceutical, acquiring global rights to a first-in-class JAK/ROCK inhibitor. This strategic move is poised to enhance Sanofi’s portfolio in both hematology and immunology, addressing critical therapeutic areas with unmet needs. The JAK/ROCK pathway is recognized for its potential in modulating immune responses and…

Moderna Settles Covid Vaccine Patent Dispute for $950 Million with Arbutus and Roivant

March 14, 2026
Moderna is set to pay $950 million to resolve a protracted patent dispute concerning its Covid-19 vaccine with Arbutus Biopharma and Roivant’s subsidiary Genevant. This settlement, announced on Tuesday, marks a significant financial commitment from Moderna as it seeks to put an end to legal uncertainties that have loomed over its vaccine development. The resolution…

Ongoing Cases